Bragar eagel & squire, p.c. announces that a class action lawsuit has been filed against sarepta therapeutics, inc. (nasdaq: srpt) and encourages sarepta investors to contact the firm

New york--(business wire)--bragar eagel & squire, p.c. announces that a class action lawsuit has been filed in the united states district court for southern district of new york on behalf of all investors that purchased sarepta therapeutics, inc. (nasdaq: srpt) securities between september 6, 2017 and august 19, 2019 (“the “class period”). investors have until october 29, 2019 to apply to the court to be appointed as lead plaintiff in the lawsuit. click here to participate in the action. on august 19, 2019, sarepta announced receipt of a complete response letter (“crl”) from the fda regarding the company’s nda seeking accelerated approval of golodirsen for the treatment of dmd. sarepta disclosed that “[t]he crl generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides.” on this news, sarepta’s stock price fell $18.24 per share, or 15.16%, to close at $102.07 per share on august 20, 2019. the complaint, filed on august 30, 2019, alleges that throughout the class period defendants made materially false and misleading statements regarding sarepta’s business, operational and compliance policies. specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) golodirsen posed significant safety risks to patients; (ii) consequently, the nda package for golodirsen’s accelerated approval was unlikely to receive fda approval; and (iii) as a result, sarepta’s public statements were materially false and misleading at all relevant times. if you purchased sarepta securities during the class period, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact brandon walker or melissa fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. there is no cost or obligation to you. bragar eagel & squire, p.c. is a new york-based law firm concentrating in commercial and securities litigation. for additional information concerning the sarepta lawsuit, please go to https://bespc.com/srpt. for additional information about bragar eagel & squire, p.c. please go to www.bespc.com. attorney advertising. prior results do not guarantee similar outcomes.
SRPT Ratings Summary
SRPT Quant Ranking